Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial

Title
Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial
Authors
Soukhathammavong, P; Odermatt, P; Sayasone, S; Vonghachack, Y; Vounatsou, P; Hatz, C; Akkhavong, K; Keiser, J
Issue Date
2011
Publisher
ELSEVIER SCIENCE INC
Citation
LANCET INFECTIOUS DISEASES; Vol.11 2; 110-118
Abstract
Background Praziquantel is the only drug available for treatment of Opisthorchis viverrini, although in-vivo studies point to activity of mefloquine, artesunate, and tribendimidine against this liver fluke. We aimed to assess the efficacy and safety of these drugs compared with that of praziquantel in patients with 0 viverrini infection. Methods We did a randomised open-label trial between February and April, 2010, in the Saysetha district, Attapeu Province, Laos. Eligible patients were school children aged 10-15 years who had 0 viverrini infections. Patients were randomly assigned to one of five different treatment groups by use of a computer-generated randomisation code. We assessed efficacy as cure rate and egg reduction rate in intention-to-treat and per-protocol analyses. The trial was registered with Current Controlled Trials, ISRCTN23425032. Results 125 children were randomly assigned: 25 received mefloquine, 24 artesunate, 24 mefloquine-artesunate, 27 tribendimidine, and 25 praziquantel. 19 patients were lost to follow-up. In the intention to treat analysis, 14 patients receiving praziquantel were cured compared with none with mefloquine, one with artesunate (odds ratio 0-03, 95% CI 0.004-0.29), one with mefloquine-artestmate (0.03,0.004-0.29), and 19 with tribendimidine (1.87,0.60-5.85). Egg reduction rate was 98.4% for praziquantel, 30.2% for mefloquine (egg reduction-rate ratio 1-61,95% CI 0-21-0.72), 31-5% for artesunate (0.43, 0.23-0.80), 41-3% for mefloquine-artesunate (0.60, 0.31-1.10), and 99-3% for tribendimidine (1-00,0.44-2.30). Most adverse events were mild or moderate and affected all treatment groups; serious adverseevents-vertigo, nausea, vomiting, and anxiety-were reported only by patients taking mefloquine or mefloquine-artesunate. Interpretation Tribendimidine seems to be at least as efficacious as the drug of choice, praziquantel, for the treatment of 0 viverrini infections; both drugs were well tolerated. Mefloquine, artesunate, and mefloquine-artesunate did not show an effect. Tribendimidine should be further investigated with large clinical trials.
URI
http://hdl.handle.net/11267/2042
ISSN
1473-3099
Appears in Collections:
3.University of Health Sciences > Faculty of basic sciences > Journal articles
Files in This Item:

qrcode

Items in LAOSpace are protected by copyright, with all rights reserved, unless otherwise indicated.